The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending Talzenna (talazoparib), an oral poly polymerase inhibitor.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
